These data all revealed the key roles of ERG and MYCN in the propagation of CML cells with acquired imatinib resistance as SETD2 targets modulated by H3K36me3 alterations. This evidence concerns the gene ERG and chronic myelogenous leukemia, BCR-ABL1 positive.